---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-161800"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2026-04-17T23:59:59+00:00"
generated_at: "2026-05-15T05:31:50.620535+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines issues $500M 0.50% convertible notes due 2033

## Summary
- Issued $500M 0.50% Convertible Senior Notes due 2033 under indenture with U.S. Bank Trust as trustee.
- Initial conversion price ~$198.80/share (5.0302 shares per $1,000 principal).
- Notes are senior unsecured, redeemable after May 2030 if stock >130% conversion price for 20 of 30 trading days.
- Holders may convert before Feb 2033 only upon specified events; after that anytime until maturity.
- Fundamental change triggers repurchase right at 100% principal plus accrued interest.

## SEC filing metadata
- accession: 0001193125-26-161800
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2026-04-17T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312526161800/0001193125-26-161800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312526161800/d19920d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-161800
- JSON: https://secwatch.observer/filing/0001193125-26-161800.json
- Plain text: https://secwatch.observer/filing/0001193125-26-161800.txt

## Key facts
- Debt Financings
  Revolution Medicines, Inc. incurred convertible notes of $500,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 0.50% per annum maturing May 1, 2033.
  - Instrument: convertible notes
  - Principal: $500,000,000 aggregate principal amount
  - Counterparty: U.S. Bank Trust Company, National Association
  - Rate: 0.50% per annum
  - Maturity: May 1, 2033
  - Event: incurrence
  source text: On April 17, 2026, Revolution Medicines, Inc. (the “Company”) issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2033 (the “Notes”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312526161800/0001193125-26-161800-index.htm
- Material Agreements
  Revolution Medicines, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $500,000,000 aggregate principal amount (effective 2026-04-17).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: U.S. Bank Trust Company, National Association
  - Value: $500,000,000 aggregate principal amount
  - Effective: 2026-04-17
  source text: On April 17, 2026, Revolution Medicines, Inc. (the “Company”) issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2033 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of April 17, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a First Supplemental Indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of April 17, 2026, between the Company and the Trustee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628171/000119312526161800/0001193125-26-161800-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.